Modern medical diagnostics is impossible without physical-chemical analysis. Most of biologically significant substances possess electrochemical activity and can be well-detected by means of electro-analytical methods. De facto, a particular method has become a standard one among the researchers of other countries: a sample is split in a chromatographer, its components are identified by the time they hold within a column and by their electrochemical behavior, while their quantity is identified on the basis of peak signal amplitude and space (e.g. US patent #6,558,955 dated 06.05.2003 Methodology for Predicting and/or Diagnosing Disease). Such analysis can be performed, for instance, by a system of high-performance liquid chromatography (HPLC) with a multichannel coulometric detector made by DIONEX/ESA Products (www.esainc.com), Namely CoulArray® Multi-Channel ECD system, which sometimes in terms of sensitivity and selectivity is better than HEFC systems with mass-spectrometer detector used by Metabolon Company (www.metabolon.com). The list of diseases that can be detected by means of patented methods is far longer, than the list of diseases that must be identified by a mobile diagnostic device (e.g., US patent #7,947,453 dated 24.05.2011 Methods for Drug Discovery, Disease Treatment, and Diagnosis Using Metabolomics). Modern methods for recognition of images combined with high selectivity of the system provide for diagnostics per general concept of metabolites (i.e. metabolic profile) in a sample rather than per separate biomarkers. However, high cost of the equipment is still the main obstacle preventing integration of these methods in general medical practice. The proposed concept of Mobile Diagnostic Device is based on comparison of a metabolic profile of the sample (i.e. its electrochemical image – composite 3D electrochemical signal) with signals from the database. Electrochemical image of the sample is obtained by means of upgraded method of electrochemical analysis of fluid (RF patent №2382354 dated 20.02.2010) using some know-hows of the applicants. At that, composite 3D electrochemical signal is obtained by means of portable tester which transmits it for further processing at a remote centre; and technically challenging stage of chromatographic separation of a sample is replaced by electro kinetic separation. We assume that this concept suits the detection of monoclonal protein (M-protein or Bence Jones protein) by means of electrophoresis of protein fractions in patient’s urine to reveal myeloma. At that, selectivity of our electrochemical detector combines two stages – analysis of protein fractions and identification of M-protein in one measurement.